Latest News on LMAT

Financial News Based On Company


Advertisement
Advertisement

Be Sure To Check Out LeMaitre Vascular, Inc. (NASDAQ:LMAT) Before It Goes Ex-Dividend

https://simplywall.st/stocks/us/healthcare/nasdaq-lmat/lemaitre-vascular/news/be-sure-to-check-out-lemaitre-vascular-inc-nasdaqlmat-before
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is about to trade ex-dividend, with shareholders needing to purchase shares before November 19th to receive the upcoming US$0.25 dividend. The company boasts a modest payout ratio of 34% of profits and 32% of free cash flow, indicating sustainability. Furthermore, LeMaitre Vascular has demonstrated strong earnings growth of 21% per annum over the past five years and an average annual dividend increase of 19% over the last decade.

Earnings And 2026 Guidance Might Change The Case For Investing In LeMaitre Vascular (LMAT)

https://simplywall.st/stocks/us/healthcare/nasdaq-lmat/lemaitre-vascular/news/earnings-and-2026-guidance-might-change-the-case-for-investi
LeMaitre Vascular reported its third-quarter 2026 results, including sales of US$67.97 million and net income of US$15.02 million, while affirming a US$0.25 quarterly dividend. The company also issued updated 2026 guidance, emphasizing price-driven organic growth and operating income expansion, which places increased scrutiny on margin execution and tissue supply projects. Investors are now evaluating how this new guidance impacts the investment thesis, particularly regarding the company's pricing power and operational risks.

Lemaitre Vascular stock hits 52-week low at 78.22 USD

https://www.investing.com/news/company-news/lemaitre-vascular-stock-hits-52week-low-at-7822-usd-93CH-5023057
LeMaitre Vascular Inc (LMAT) stock has fallen to a 52-week low of $78.22, marking a 34% drop from its high and an 18% decline in the last six months. Despite this, the company has a strong record of raising dividends for 16 years and a "GREAT" financial health score, suggesting potential undervaluation according to InvestingPro. The recent Q3 earnings showed sales slightly above estimates but adjusted EPS fell short, leading analysts to revise price targets downwards while maintaining positive ratings on strong product demand.

Lemaitre Vascular stock hits 52-week low at 78.22 USD By Investing.com

https://uk.investing.com/news/stock-market-news/lemaitre-vascular-stock-hits-52week-low-at-7822-usd-93CH-4978660
Lemaitre Vascular (LMAT) stock has dropped to a 52-week low of $78.22, a 34% decrease from its high, reflecting a challenging year with a 12.65% decline over the past 12 months. Despite this, the company maintains strong fundamentals, including 16 years of dividend increases and a "GREAT" financial health score, suggesting it may be undervalued. Recent Q3 earnings slightly exceeded sales estimates but missed adjusted EPS, leading to revised price targets from analysts.

How (LMAT) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/34/How_LMAT_Movements_Inform_Risk_Allocation_Models_111226090402_1794492242.html
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT) using AI models, revealing weak near and mid-term sentiment, but a neutral long-term outlook. It identifies an exceptional 59.9:1 risk-reward setup targeting a 17.4% gain versus 0.3% risk. The report details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for various risk profiles and holding periods, complete with entry, target, and stop loss levels.
Advertisement

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Has Consensus Target Price of $105.60

https://www.marketbeat.com/instant-alerts/consensus-lemaitre-vascular-inc-nasdaq-lmat-stock-has-consensus-target-price-of-10560-2026-11-09/
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus "Hold" rating from nine brokerages, with an average 12-month price target of $105.60 against its opening share price of $80.89. The company's third-quarter revenue increased by 11.3% year-over-year to $67.97 million, slightly exceeding estimates, but its EPS of $0.65 missed the consensus and was down from the previous year. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, translating to an annual dividend of $1.00 and a 1.2% yield.

Boston Trust Walden Corp Makes New Investment in LeMaitre Vascular, Inc. $LMAT

https://www.marketbeat.com/instant-alerts/filing-boston-trust-walden-corp-makes-new-investment-in-lemaitre-vascular-inc-lmat-2026-11-06/
Boston Trust Walden Corp has initiated a new position in LeMaitre Vascular (NASDAQ:LMAT), acquiring 345,634 shares valued at approximately $28.5 million. This investment comes as LeMaitre Vascular reported mixed third-quarter results, with revenue exceeding estimates but earnings per share falling short. The company also declared a quarterly dividend of $0.25 per share, and analysts currently hold an average "Hold" rating with a consensus price target of $105.60.

LeMaitre to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/06/3397889/10507/en/lemaitre-to-participate-in-upcoming-investor-conferences.html
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its CFO, Dorian LeBlanc, will participate in three upcoming investor conferences: the Stifel 2026 Healthcare Conference on November 12, 2026, the Jefferies 2026 Global Healthcare Conference on November 17, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 3, 2026. The company specializes in devices, implants, and services for treating peripheral vascular disease.

LeMaitre Vascular Q3 Earnings Call Highlights

https://es.tradingview.com/news/marketbeat:79a151e5a094b:0-lemaitre-vascular-q3-earnings-call-highlights/
LeMaitre Vascular reported 12% organic sales growth in Q3 2026, driven by higher prices and unit volumes, and reiterated its full-year organic growth outlook while lowering its gross margin forecast. The company acquired a portfolio of vascular devices from B. Braun for $19.2 million and is managing the transition challenges associated with this acquisition. Additionally, LeMaitre Vascular is expanding Artegraft internationally and addressing capacity constraints for RestoreFlow.

Wells Fargo cuts LeMaitre Vascular stock price target on margin miss

https://ca.investing.com/news/stock-market-news/wells-fargo-cuts-lemaitre-vascular-stock-price-target-on-margin-miss-93CH-4933618
Wells Fargo has lowered its price target for LeMaitre Vascular shares from $94 to $86, maintaining an Equal Weight rating, after the company's third-quarter results showed a miss on gross and operating margins, despite slightly beating revenue estimates. The company reported third-quarter sales of $68 million, up 12% organically, but earnings per share of $0.65 fell short of the $0.69 estimate. This adjustment reflects analyst sentiment, with 8 analysts revising earnings downwards, and the stock is considered overvalued at current levels according to InvestingPro's Fair Value analysis.
Advertisement

Citizens cuts LeMaitre Vascular stock price target on Q3 results

https://www.investing.com/news/analyst-ratings/citizens-cuts-lemaitre-vascular-stock-price-target-on-q3-results-93CH-5002700
Citizens has lowered its price target for LeMaitre Vascular (NASDAQ:LMAT) shares to $110 from $127, while maintaining a Market Outperform rating. This adjustment comes after the company's Q3 2026 results, which showed in-line sales but slight misses on adjusted EPS and EBITDA. Despite the lowered target, Citizens believes the company's operations remain healthy and it is well-positioned for margin expansion.

LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $102.29, Implies 16% Upside

https://www.tradingview.com/news/tradingview:77b2a5eaeaaa2:0-lemaitre-vascular-inc-stock-12-month-price-target-cut-to-102-29-implies-16-upside/
Seven analysts have revised the average 12-month price target for LeMaitre Vascular, Inc. (LMAT) stock down to $102.29 from $107, with individual forecasts ranging from $81 to $132 per share. This updated target suggests a potential 16% upside based on the November 4 closing price. The consensus rating among eight covering analysts remains "Buy," with four "Buy" recommendations and four "Hold" recommendations.

LeMaitre Vascular earnings up next as investors seek Q3 rebound By Investing.com

https://www.investing.com/news/earnings/lemaitre-vascular-earnings-up-next-as-investors-seek-q3-rebound-93CH-5000144
LeMaitre Vascular Inc. is set to report its third-quarter earnings, with analysts expecting $0.69 per share on revenue of $67.74 million, marking an 11% year-over-year increase for both metrics. Investors are closely watching for signs of operational improvement and recovery after the company missed Q2 expectations, experienced a sharp stock selloff, and issued a Class II recall for some of its devices. The company is also undergoing a leadership transition, adding another layer of scrutiny to the upcoming earnings report.

LMAT: LeMaitre Vascular Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/lemaitre-vascular-inc-filed-sec-form-8-k-results-of-operations-6773272
LeMaitre Vascular Inc. reported preliminary Q3 2026 sales of $68.0 million, an 11% increase year-over-year, with EPS of $0.65. The company also announced a $100 million share repurchase authorization, a $0.25 quarterly dividend, and the acquisition of certain vascular assets from B. Braun for $19.2 million. Despite increased operating expenses, management projects 2026 sales growth of 11% and EPS growth of 18%.

LeMaitre Vascular earnings missed by $0.04, revenue topped estimates

https://uk.investing.com/news/earnings/lemaitre-vascular-earnings-missed-by-004-revenue-topped-estimates-4958759
LeMaitre Vascular (NASDAQ: LMAT) reported its third-quarter earnings, missing analyst EPS estimates by $0.04 with an EPS of $0.65, but exceeding revenue estimates with $68M against a consensus of $67.74M. The company also provided Q4 and full-year 2026 revenue guidance, which came in slightly below analyst consensus. Following the report, the stock price closed at $87.92, showing an increase over the last three and twelve months, and its financial health is rated "great performance" by InvestingPro.
Advertisement

LeMaitre Vascular Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:723226:0-lemaitre-vascular-q3-2026-earnings-call-is-live/
LeMaitre Vascular's Q3 2026 earnings call has just started, where executives will discuss the latest financial results and answer questions from Wall Street analysts. Investors following LMAT should tune in to hear management's insights on the numbers and potential future outlook, as commentary can significantly influence market perception. This call provides an opportunity for new information to be released that could impact the stock.

LeMaitre’s (NASDAQ:LMAT) Q3 2026 sales beat estimates but stock drops 11.9%

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-4-lemaitres-nasdaqlmat-q3-2026-sales-beat-estimates-but-stock-drops-119
LeMaitre Vascular (NASDAQ: LMAT) reported Q3 2026 revenue of $67.97 million, surpassing Wall Street estimates, but its stock dropped 11.9% due to disappointing Q4 revenue guidance and a GAAP profit miss. Despite solid historical revenue and EPS growth, the company's full-year EPS outlook also fell short of analyst consensus, leading to a weaker quarter overall.

LeMaitre Q3 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/04/3395840/10507/en/lemaitre-q3-2026-financial-results.html
LeMaitre Vascular, Inc. reported strong Q3 2026 results with sales up 11% to $68.0 million and organic growth of 12%. The company announced a quarterly dividend of $0.25/share and provided optimistic guidance for Q4 and the full year 2026, driven by biologics and a recent acquisition. LeMaitre also detailed its financial performance, business outlook, and non-GAAP adjustments.

LeMaitre earnings: what to look for from LMAT

https://www.tradingview.com/news/stockstory:7a7a9b163094b:0-lemaitre-earnings-what-to-look-for-from-lmat/
LeMaitre Vascular (LMAT) is set to report earnings, with analysts expecting a 10.4% year-on-year revenue growth. The company missed revenue expectations last quarter and has done so multiple times over the last two years. While some peers in the healthcare equipment segment have shown positive results, LeMaitre's stock price has remained unchanged, heading into earnings with an average analyst price target of $107 against its current share price of $81.75.

LeMaitre Vascular, Inc. (LMAT) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4771_QuantitativeReport_1793145600000/
An Argus quantitative report, published on October 28, 2026, discusses LeMaitre Vascular Inc. (LMAT), a manufacturer and distributor of medical devices for peripheral vascular disease. The report provides an earnings estimate, a current price of $81.04, and a price target for LMAT. The article encourages users to upgrade for premium screener tools and exclusive reports.
Advertisement

30,639 LeMaitre Vascular, Inc. $LMAT Shares Purchased by Bridge City Capital LLC

https://www.marketbeat.com/instant-alerts/filing-30639-lemaitre-vascular-inc-lmat-shares-purchased-by-bridge-city-capital-llc-2026-11-02/
Bridge City Capital LLC significantly increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 35.5% in the third quarter, acquiring an additional 30,639 shares to hold a total of 116,980 shares valued at $9.66 million. Despite this institutional buying, the company's recent quarterly results missed analyst expectations for both earnings and revenue, leading to a weakened analyst sentiment and several downgrades. The consensus rating for LMAT is currently "Hold" with an average target price of $110.60.

Understanding Momentum Shifts in (LMAT)

https://news.stocktradersdaily.com/news_release/40/Understanding_Momentum_Shifts_in_LMAT_110226091202_1793628722.html
This article analyzes Lemaitre Vascular Inc. (NASDAQ: LMAT), highlighting conflicting sentiment and a mid-channel oscillation pattern. AI models propose three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, indicating varying support and resistance levels.

LeMaitre Vascular, Inc. (LHU.F) Analyst Insights, Price Targets & Recommendations - Yahoo Finance

https://ca.finance.yahoo.com/quote/LHU.F/analyst-insights/
This article provides analyst insights, price targets, and recommendations for LeMaitre Vascular, Inc. (LHU.F). It lists recent upgrades and downgrades from firms like Wells Fargo, Barrington Research, and Citizens. The company's upcoming Q3 2026 earnings call is scheduled for November 4, 2026.

LeMaitre Vascular Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-4-lemaitre-vascular-inc-stock/
LeMaitre Vascular (NASDAQ:LMAT) is estimated to report its Q3 2026 earnings on Wednesday, November 4, 2026, after market close, with a conference call scheduled for 5:00 PM ET. Analysts anticipate the company will post earnings of $0.6860 per share on revenue of $67.39 million, representing a year-over-year increase in both metrics. The company has a history of beating EPS estimates in 5 out of its last 8 quarters.

LeMaitre Vascular (LMAT) Expected to Announce Earnings on Wednesday

https://www.marketbeat.com/instant-alerts/upcoming-lemaitre-vascular-lmat-expected-to-announce-earnings-on-wednesday-2026-10-28/
LeMaitre Vascular (LMAT) is anticipated to release its Q3 2026 earnings after market close on Wednesday, November 4th, with analysts projecting earnings of $0.686 per share and $67.39 million in revenue. The company's previous quarter missed expectations with $0.74 EPS against an $0.81 estimate, and its revenue of $70.38 million was below the $71.47 million forecast. Investor sentiment remains cautious, with LMAT shares trading at $84.19 and analysts holding an average "Hold" rating with a $110.60 price target.
Advertisement

LeMaitre Vascular, Inc. Estimates – SWB:LHU

https://www.tradingview.com/symbols/SWB-LHU/financials-estimates/
This article from TradingView provides an overview of LeMaitre Vascular, Inc. (SWB:LHU) financial estimates. It highlights reported financial data and analyst estimates across various financial statements and valuation metrics. Users can compare actual results with average, high, and low estimates, and visualize trends over time.

LeMaitre Vascular, Inc. Estimates – NASDAQ:LMAT

https://www.tradingview.com/symbols/NASDAQ-LMAT/financials-estimates/
This page provides financial estimates for LeMaitre Vascular, Inc. (NASDAQ: LMAT), allowing users to explore reported financial data and analyst estimates across various statements and valuation metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time, covering income statement, balance sheet, and cash flow.

LeMaitre Vascular, Inc. Estimates – LS:A0LB2B

https://www.tradingview.com/symbols/LS-A0LB2B/financials-estimates/
This page provides financial estimates for LeMaitre Vascular, Inc. (A0LB2B) on TradingView. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics, compare actual results with estimates, and visualize trends over time. The content focuses on fundamental analysis, offering detailed financial information without providing investment advice.

LeMaitre Vascular, Inc. (LMAT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/LMAT/
This article provides a detailed overview of LeMaitre Vascular, Inc. (LMAT), including its current stock price, recent performance metrics, and financial highlights. It covers key financial data, analyst insights, and a description of the medical devices and implants the company develops, manufactures, and markets. The company's overview details its product offerings, market reach, and corporate structure.

LeMaitre Vascular, Inc. (LMAT) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/LMAT/
This article provides a comprehensive overview of LeMaitre Vascular, Inc. (LMAT), a company specializing in medical devices for vascular surgery. It includes real-time stock data, historical performance, key financial metrics, company profile, recent news, and analyst insights. The company develops and markets a wide range of products globally, from allografts and catheters to various biologic patches and vascular grafts.
Advertisement

Analysts set USD 110.60 target for LeMaitre Vascular stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/analysts-set-usd-110-60-target-for-lemaitre-vascular-stock/70376011
Nine research firms have given LeMaitre Vascular (LMAT) a "Hold" consensus with an average 12-month target of USD 110.60, representing a 32.99% upside from its recent Nasdaq price. The company reported Q2 2026 revenue of USD 70.38 million and diluted EPS of USD 0.74, both slightly missing analyst estimates. LeMaitre Vascular is set to release its Q3 2026 results on November 4, 2026.

Annex Advisory Services LLC Sells 226,849 Shares of LeMaitre Vascular, Inc. $LMAT

https://www.marketbeat.com/instant-alerts/filing-annex-advisory-services-llc-sells-226849-shares-of-lemaitre-vascular-inc-lmat-2026-10-18/
Annex Advisory Services LLC significantly reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by selling 226,849 shares, decreasing its holdings by 91.4%. Despite this, other institutional investors like Copeland Capital Management and Corient Private Wealth increased their positions, with institutional ownership remaining high at 84.64%. The stock recently traded near $80.82 after the company missed quarterly earnings and revenue estimates, and analysts currently hold a consensus "Hold" rating with an average price target of $110.60.

LeMaitre Vascular stock reports on November 4, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/lemaitre-vascular-stock-reports-on-november-4-2026/70351347
LeMaitre Vascular (LMAT) is scheduled to release its third-quarter 2026 financial results on November 4, 2026, after market close. The stock's price-to-earnings ratio was 28.36, and its market capitalization was USD 1.8 billion as of October 16, 2026. The company's stock stood at USD 80.82 on October 16, down 2.81 percent from its prior close, and was 3.32 percent above its 52-week low.

Barrington Maintains LeMaitre Vascular(LMAT.US) With Buy Rating, Maintains Target Price $95

https://www.moomoo.com/news/post/1001054854/barrington-maintains-lemaitre-vascular-lmatus-with-buy-rating-maintains-target
Barrington has reiterated its Buy rating on LeMaitre Vascular (LMAT.US) and maintained its target price at $95. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Barrington keeps USD 95.00 target for LeMaitre Vascular stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barrington-keeps-usd-95-00-target-for-lemaitre-vascular-stock/70331330
Barrington analyst Michael Petusky has maintained a Buy rating and a USD 95.00 price target for LeMaitre Vascular (LMAT) stock. The company is set to release its third-quarter results on November 4, 2026. While the stock is trading near its 52-week low, the target price represents a significant upside from its current Nasdaq price.
Advertisement

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Rated "Hold" by Sell-Side Analysts

https://www.marketbeat.com/instant-alerts/consensus-lemaitre-vascular-inc-nasdaq-lmat-stock-rated-hold-by-sell-side-analysts-2026-10-15/
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average "Hold" rating from sell-side analysts, with five out of nine firms recommending a hold and four recommending a buy. The average 12-month price target for the stock is $110.60. The company recently reported quarterly earnings that missed analyst expectations for both EPS and revenue, though revenue still grew by 9.6% year-over-year.

LeMaitre Vascular, Inc. $LMAT Stock Bought by Copeland Capital Management LLC

https://www.marketbeat.com/instant-alerts/filing-lemaitre-vascular-inc-lmat-stock-bought-by-copeland-capital-management-llc-2026-10-14/
Copeland Capital Management LLC increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 10.1%, making it their sixth-largest holding. Other institutional investors also adjusted their positions in the medical instruments supplier. The company recently announced a quarterly dividend and analysts have a "Hold" consensus rating with a price target of $110.60.

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

https://finance.yahoo.com/markets/stocks/articles/lemaitre-announce-third-quarter-2026-204900108.html
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after market close. The company will also host a conference call at 5:00 PM EST on the same day to discuss the results, business highlights, and company outlook. Interested parties can register online for access to the live call or access an audio webcast via the company's investor relations website.

Precision Trading with Lemaitre Vascular Inc. (LMAT) Risk Zones

https://news.stocktradersdaily.com/news_release/132/Precision_Trading_with_Lemaitre_Vascular_Inc._LMAT_Risk_Zones_101226115201_1791863521.html
This article provides a precision trading analysis for Lemaitre Vascular Inc. (LMAT), highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—each with specific entry zones, targets, and stop losses, emphasizing a significant 57.8:1 risk-reward setup. The analysis also includes multi-timeframe signal analysis with support and resistance levels.

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

https://www.globenewswire.com/news-release/2026/10/12/3379261/0/en/lemaitre-will-announce-third-quarter-2026-earnings-results-on-november-4-2026.html
LeMaitre Vascular, Inc. will release its third-quarter 2026 financial results on Wednesday, November 4, 2026, after the market closes. The company has scheduled a conference call for 5:00 PM EST on the same day to discuss the results, business highlights, and company outlook. Interested parties can register online to access the live call or view the audio webcast via replay at ir.lemaitre.com.
Advertisement

LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026

https://www.globenewswire.com/news-release/2026/10/12/3379261/10507/en/lemaitre-will-announce-third-quarter-2026-earnings-results-on-november-4-2026.html
LeMaitre Vascular, Inc. announced it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST on the same day to discuss the results, business highlights, and company outlook. LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease.

LeMaitre Vascular, Inc. (LMAT) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4771_QuantitativeReport_1791331200000
Argus has lowered its target price for LeMaitre Vascular, Inc. (LMAT) to $87.00, while the current stock price is $80.69. LeMaitre Vascular Inc. manufactures and distributes medical devices for peripheral vascular disease. The report was published on October 7, 2026.

LeMaitre Vascular, Inc. (LMAT) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_4771_QuantitativeReport_1791331200000
Argus has lowered its target price for LeMaitre Vascular, Inc. (LMAT) to $87.00. The company manufactures and distributes medical devices for peripheral vascular disease treatment, with its current stock price at $80.69. This report was published on October 7, 2026.

LeMaitre Vascular (NASDAQ:LMAT): A Quality Stock for Long-Term Investors

https://www.chartmill.com/news/LMAT/Chartmill-55973-LeMaitre-Vascular-NASDAQLMAT-A-Quality-Stock-for-Long-Term-Investors
The article identifies LeMaitre Vascular (NASDAQ:LMAT) as a quality stock for long-term investors, based on a rigorous quantitative screening process designed to find exceptional businesses. The company demonstrates strong financial health with high profitability, growing margins, and efficient capital use, despite some caveats like share dilution and expected growth deceleration. LMAT's metrics, including significant EBIT growth and robust free cash flow, support its classification as a durable compounder.

LeMaitre Vascular Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-5-lemaitre-vascular-inc-stock/
LeMaitre Vascular (LMAT) is scheduled to report its Q3 2026 earnings on Thursday, November 5, 2026, after market close, with a conference call at 5:00 PM ET. Analysts anticipate earnings of $0.6860 per share on revenues of $67.39 million, marking a projected year-over-year increase of 10.6% in EPS and 10.4% in revenue. The company has a history of beating EPS consensus estimates in 5 out of its last 8 quarters.
Advertisement

LeMaitre Vascular stock costs EUR 70.50 before November results

https://www.ad-hoc-news.de/boerse/news/nebenwerte/lemaitre-vascular-stock-costs-eur-70-50-before-november-results/70266075
LeMaitre Vascular's stock was trading at EUR 70.50 on October 8, 2026, slightly down from its prior close, ahead of its November 5, 2026, quarterly results. The company reported Q2 sales of USD 70.38 million, up 9.60% year-over-year, but this was below analyst expectations for both revenue and earnings per share. Investors are now focused on execution and guidance delivery in the upcoming report.

Do LeMaitre Vascular's (NASDAQ:LMAT) Earnings Warrant Your Attention?

https://www.moomoo.com/news/post/1000757889/do-lemaitre-vascular-s-nasdaq-lmat-earnings-warrant-your-attention
This article analyzes LeMaitre Vascular's earnings to determine if they warrant investor attention. It likely examines financial performance, growth metrics, and market sentiment to assess the company's investment potential based on its recent results. The core question is whether the reported earnings indicate a compelling reason to consider LMAT stock.

Barrington keeps Buy rating for LeMaitre Vascular stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/barrington-keeps-buy-rating-for-lemaitre-vascular-stock/70247460
Barrington has maintained a Buy rating and a USD 95.00 price target for LeMaitre Vascular stock. This decision follows the company's second-quarter 2026 sales of USD 70.38 million, a 9.60 percent increase year over year, despite diluted earnings per share of USD 0.74 missing the USD 0.81 consensus estimate. The analyst firm's target remains significantly above the primary exchange quote, reflecting continued confidence in the company's operational growth.

LeMaitre Vascular, Inc. (LMAT) Stock forecasts

https://uk.finance.yahoo.com/research/reports/ARGUS_4771_QuantitativeReport_1790726400000
This article is a placeholder for stock forecasts for LeMaitre Vascular, Inc. (LMAT). However, the content provided is an error message and typical Yahoo Finance navigation, indicating that the actual forecast data is not available.

LMAT5964284 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-LMAT5964284/profile/
This article provides a detailed bond profile for LMAT5964284, issued by LeMaitre Vascular, Inc. It outlines key facts such as the issue and maturity dates, face value, and minimum denomination. The profile also details the semi-annual fixed-rate coupon payments, including the next coupon dates, interest rates, and amounts.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement